Theratechnologies (TSE:TH) had its target price reduced by equities research analysts at Mackie from C$8.15 to C$7.00 in a report released on Friday, BayStreet.CA reports. The brokerage currently has a “hold” rating on the stock. Mackie’s target price suggests a potential upside of 23.89% from the company’s current price.
Several other research firms also recently issued reports on TH. Stifel Nicolaus began coverage on shares of Theratechnologies in a research note on Tuesday, May 14th. They set a “buy” rating and a C$15.00 price target on the stock. Royal Bank of Canada set a $184.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, July 3rd. Finally, National Bank Financial lifted their price target on shares of Wesdome Gold Mines from C$6.00 to C$6.25 and gave the stock an “outperform” rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of C$9.56.
Shares of TH stock traded down C$0.54 during mid-day trading on Friday, reaching C$5.65. The company’s stock had a trading volume of 270,181 shares, compared to its average volume of 155,748. The firm’s 50 day moving average is C$6.75. Theratechnologies has a 12-month low of C$5.17 and a 12-month high of C$11.45. The company has a debt-to-equity ratio of 145.32, a current ratio of 2.46 and a quick ratio of 1.97. The stock has a market cap of $503.71 million and a price-to-earnings ratio of -115.10.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Theratechnologies during the 1st quarter valued at about $96,000. Mesirow Financial Investment Management Inc. acquired a new position in Theratechnologies during the 1st quarter valued at about $328,000. LLBH Private Wealth Management LLC acquired a new position in Theratechnologies during the 1st quarter valued at about $1,735,000. Finally, Monarch Partners Asset Management LLC acquired a new position in Theratechnologies during the 1st quarter valued at about $4,256,000.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Read More: Tariff
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.